B
Biosortia Pharmaceuticals
Biosortia is working on new drugs from deep access to the chemistry of the microbiome for immuno-oncology & immunological therapeutics
About Biosortia Pharmaceuticals
Biosortia Pharmaceuticals is a drug discovery and development company with a focus on accessing novel chemistry from microorganisms found in aquatic microbiomes. The company utilizes a proprietary technology to obtain and study these microorganisms, many of which are difficult to cultivate using traditional methods. This allows them to explore a new range of small molecules for potential therapeutic applications.
The company's primary therapeutic areas of interest are immuno-oncology and immunology. By identifying and developing new drug candidates from these previously untapped natural sources, Biosortia aims to provide new options for treating a variety of diseases. Their business model involves forming strategic partnerships with other pharmaceutical companies to further develop and commercialize the drug candidates they discover.
Biosortia operates in the biotechnology and pharmaceutical sectors, serving as a source of new drug leads for the broader pharmaceutical industry. The company's approach of mining the microbiome for new chemical entities positions it at the intersection of biotechnology, drug discovery, and natural product chemistry.
Source: Dealroom company dataNews
Open roles
Biosortia Pharmaceuticals in the Columbus ecosystem
The Biosortia Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Keiretsu Forum
Source: Dealroom Talent Intelligence.
See Biosortia Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

